Sanara MedTechSMTI +2.48%72 PB Ratio is 32.40 as of Jul. 02, 2026, which is 325% above its 10-year median of 7.62. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.61 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Sanara MedTech ranks worse than 97.84% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-02), Sanara MedTech's share price is $24.85. Sanara MedTech's Book Value per Share for the quarter that ended in Mar. 2026 was $0.77. Hence, Sanara MedTech's PB Ratio of today is 32.40.
The historical rank and industry rank for Sanara MedTech's PB Ratio or its related term are showing as below:
SMTI'
s PB Ratio Range Over the Past 10 Years
Min: 4.52 Med: 7.62 Max: 55.48
Current: 32.26
During the past 13 years, Sanara MedTech's highest PB Ratio was 55.48. The lowest was 4.52. And the median was 7.62.
SMTI's PB Ratio is ranked worse than 97.84% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs SMTI: 32.26
During the past 12 months, Sanara MedTech's average Book Value Per Share Growth Rate was -81.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -49.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sanara MedTech was 75.20% per year. The lowest was -74.30% per year. And the median was 4.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sanara MedTech PB Ratio Related Terms
Sanara MedTech PB Ratio Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sanara MedTech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Sanara MedTech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sanara MedTech (SMTI) has a PB Ratio of 32.40 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sanara MedTech and its competitors. This is 325% above median its historical median of 7.62. Over the past decade, Sanara MedTech's PB Ratio has ranged from 4.52 to 55.48. According to the industry distribution chart, Sanara MedTech ranks #770 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 97.8%.
Is Sanara MedTech's PB Ratio too high?
Sanara MedTech's current PB Ratio of 32.40 is 325% above median its 10-year median of 7.62. Over the past 10 years, this metric has ranged from a low of 4.52 to a high of 55.48. The Medical Devices & Instruments industry median PB Ratio is 2.07. Sanara MedTech's value of 32.40 is 1465.2% above this industry median. Based on the distribution chart, Sanara MedTech ranks #770 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's PB Ratio compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #770 out of 787 companies for PB Ratio. This places Sanara MedTech in the lower half of its industry. The industry median PB Ratio is 2.07. Sanara MedTech's value of 32.40 is 1465.2% above this benchmark. Historically, Sanara MedTech's own PB Ratio has ranged from 4.52 to 55.48 over the past decade. While the company's 10-year median is 7.62 vs. the industry median of 2.07, Sanara MedTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.07, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current PB Ratio of 32.40 is 1465.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current PB Ratio is 32.40, which is 325% above median its own 10-year median of 7.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.61, compared to a current price of $24.85 — trading 45.5% below its estimated fair value. The current PB Ratio is 32.40, which is 325% above median its 10-year median of 7.62 and 1465.2% above the Medical Devices & Instruments industry median of 2.07. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current PB Ratio is 32.40 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $24.85 is trading 45.5% below its estimated GF Value™ of $45.61.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
PB Ratio: 32.40 (325% above median its 10-year median of 7.62)
GF Value™: $45.61 vs. price of $24.85 (45.5% below fair value)
Industry Position: 1465.2% above the Medical Devices & Instruments median (#770 of 787)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score
Get the complete analysis for SMTI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
